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Abstract 
Aims: We evaluated a generic quality of life (QoL) Functional Status Questionnaire 
(FSQ), in patients with chronic heart failure (CHF). The FSQ assesses the 3 main 
dimensions of QoL: physical functioning, mental health and social role. It also 
includes 6 single item questions about: work status, frequency of social interactions, 
satisfaction with sexual relationships, days in bed, days with restricted activity and 
overall satisfaction with health status. The FSQ was compared to the Minnesota 
Living with Heart Failure questionnaire (MLwHF). 
Methods and Results: The FSQ was evaluated in a substudy (n=340) of the second 
Cardiac Insufficiency Bisoprolol Survival study (CIBIS-II), a placebo-controlled 
mortality trial. 265 patients (75%) patients completed both questionnaires at 6 months 
of follow-up. Both questionnaires indicated substantially impaired QoL. The FSQ 
demonstrated high internal consistency (Cronbach’s α >0.7 for all items except “social 
activity” = 0.66) and construct and concurrent validity. After 6 months, the only item 
on either questionnaire to show a difference between the placebo- and bisoprolol-
treatment groups was the single item FSQ question about “days in bed” (p = 0.018 in 
favour of bisoprolol).   
Conclusions: The FSQ performed well in this study, provided additional information 
to the MLwHF questionnaire and allowed interesting comparisons with other chronic 
medical conditions. The FSQ may be a useful general QoL instrument for studies in 
CHF. 
 
 
Key words: Heart failure, Quality of life, Functional Status Questionnaire, Minnesota 
Living with Heart Failure questionnaire.   
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Introduction 
It is widely recognised that chronic heart failure (CHF) impairs quality of life (QoL) 
more than almost any other medical condition1,2. Reduced QoL in CHF is associated 
with a worse prognosis3 and patients with advanced CHF may place more value on 
improving their QoL than they do on prolonging their life4,5. Therefore, improving 
QoL is a desirable objective of CHF treatments. There is however, uncertainty and 
debate about which instruments should be used to measure QoL in studies of CHF, 
although there is some consensus that both a ‘disease-specific’ and ‘generic’ QoL 
questionnaire should be employed6. 
 
The most widely used disease-specific instrument is the Minnesota Living with Heart 
Failure questionnaire (MLwHF)7. There has been far less agreement about the general 
QoL questionnaire used, with a variety of instruments employed in prior studies in 
CHF.  
 
The Functional Status Questionnaire (FSQ)8 is a generic questionnaire which has been 
used in other chronic incapacitating diseases such as chronic back pain9, rheumatoid 
arthritis10, chronic obstructive pulmonary disease11, Parkinson’s disease12 and 
multiple sclerosis13. The FSQ was found to be more sensitive than the New York 
Heart Association (NYHA) functional classification in predicting subsequent clinical 
deterioration in elderly patients following percutaneous aortic balloon valvuloplasty14. 
Certain components of the FSQ, mainly ‘physical functioning’ and ‘social role 
functioning’ have been used previously in conjunction with other QoL measures in 
patients with CHF3,15. However, the FSQ in its entirety has not been validated in CHF. 
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The FSQ addresses the three main dimensions of QoL, namely physical functioning 
(including basic and intermediate activities of daily living), mental health and social 
role (including social activity, quality of social interaction and work performance). In 
addition, the questionnaire includes six single items that may be relevant in patients 
with CHF: work status, frequency of social interactions, satisfaction with sexual 
relationships, days in bed, days with restricted activity and overall satisfaction with 
health status.  
 
The second Cardiac Insufficiency Bisoprolol Survival study (CIBIS-II)16, a placebo-
controlled mortality trial, provided an opportunity to evaluate the FSQ in patients with 
CHF. 
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Methods 
Patients and Study Design 
The design and principal findings of CIBIS-II have been described in detail 
elsewhere16,17. Briefly, this was a double blind, randomised, comparison of placebo 
and bisoprolol in 2647 ambulatory patients with CHF in NYHA functional class III 
(83%) or IV (17%) and with a left ventricular ejection fraction of ≤ 0.35. Eligible 
patients were commenced on bisoprolol 1.25 mg or placebo once daily and the dose 
increased progressively to 2.5 mg, 3.75 mg, 5.0 mg, 7.5 mg and 10.0 mg according to 
tolerance. The trial was stopped prematurely after a mean follow-up of 1.3 years 
because of a statistically significant reduction in the primary end-point of all-cause 
mortality, with a bisoprolol to placebo hazard ratio (and 95% confidence intervals) of 
0.66 (0.54, 0.81), p<0.0001. 
 
In a sub-group of 351 patients (180 allocated to bisoprolol and 171 allocated to 
placebo) an ancillary QoL analysis was performed simultaneously with the main study. 
All patients in this sub-group were from France, the UK and Germany. The generic 
FSQ and disease-specific MLwHF self-administered questionnaires were completed 
by patients at baseline and every 6 months thereafter for up to 2.5 years. This analysis 
focused on the data collected up until 6 months because a high proportion of 
subsequent questionnaires were not completed. 
 
QoL Instruments 
The MLwHF is a validated ‘disease-specific’ questionnaire which measures the 
effects of CHF on QoL7 (appendix 1). It assesses QoL in the past month. Briefly, the 
questionnaire evaluates two of the main dimensions of QoL: physical [8 items] and 
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emotional [5 items] health and provides summary scores for each of these dimensions. 
It is composed of 21 items in total, and in addition to physical and emotional 
dimensions it also assesses social and mental aspects of QoL. Each item is scored 
from 0-5, resulting in score ranges of 0-40 for the physical dimension and 0-25 for the 
emotional one. A total score is also provided and ranges from 0-105. In each case a 
lower score is indicative of a better QoL. 
 
The FSQ, like the MLwHF questionnaire, is a short self-administered tool concerning 
the one month period prior to completion8 (appendix 2). It includes two scales which 
assess physical function: basic activities of daily living (BADL) [3 items] and 
intermediate activities of daily living (IADL) [5 items]. Mental function is assessed by 
5 items and social or role function is assessed by work performance (if patient is in 
employment) [6 items], social activity [3 items] and quality of social interaction [5 
items]. 
The FSQ also contains six single items which ask questions about work status, days 
spent in bed due to illness, days where the patient had to curtail his/her routine 
activities because of illness, satisfaction with sexual activities, frequency of social 
interaction and a question about overall health satisfaction. There are 34 items in the 
FSQ in total. Using a simple algorithm, computer-generated scores are obtained for 
BADL, IADL, mental health, work performance, social activity and quality of 
interaction. Scores range from 0-100 and a higher score is representative of a better 
QoL, in contrast to the MLwHF questionnaire. A summary report is produced which 
displays each score on a scale and the answer to each of the single item questions. The 
developers of the FSQ described what they called “warning zones” or a range of 
scores they believed indicated when a patient had a problem requiring clinical 
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attention/investigation. The “warning zone” scores for BADL are 0-87, for IADL 0-77, 
for mental health 0-70, for work performance and social activities 0-78 and for quality 
of interactions 0-69. 
 
Evaluation of the FSQ 
The psychometric properties of the FSQ have previously been assessed and the 
instrument was found to be reliable and valid for use in the primary care setting8.  
Internal consistency (or internal reliability) is the extent to which questions within a 
domain assess the same characteristic. This was determined in the standard way using 
Cronbach’s α. Construct validity seeks agreement between a theoretical concept and a 
specific measuring device and was assessed by examining correlations between 
related and unrelated dimensions. Concurrent validity can be assessed by comparing 
an instrument to another for which there is unequivocal evidence of its validity. We 
assessed this by comparing the FSQ scores in different NYHA functional classes and 
by examining correlations between the different dimensions of the FSQ and MLwHF 
questionnaire.  
 
Statistical Analysis 
Continuous variables are expressed as means and standard deviations, categorical 
variables are expressed with percentages and related sample size. Differences in 
baseline characteristics, QoL scores and improvements in QoL during follow-up 
between patients allocated to bisoprolol and placebo were assessed using χ2 test for 
categorical variables and unpaired Wilcoxon rank sum test for continuous variables. 
Correlations within individual items of the FSQ and between FSQ items and MLwHF 
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dimensions were performed with the use of Pearson correlation coefficients. The level 
of significance was taken as two-tailed p < 0.05. 
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Results 
Baseline characteristics  
340 (97%) patients completed both questionnaires at baseline and 265 patients (75%) 
at 6 months of follow-up. 
The mean age was 63, 81% of patients were male and the aetiology of CHF was 
ischaemic in almost half, similar to the whole CIBIS-II population16. The proportion 
of patients with NYHA class IV CHF was smaller in the QoL sub-study than in the 
whole population (8% versus 17%).  
There were no significant differences in demographic and clinical baseline 
characteristics between patients allocated to bisoprolol compared to those allocated to 
placebo (tables 1 and 2).  
 
MLWHF 
The baseline MLwHF scores indicated moderately impaired QoL and were similar in 
patients randomized to bisoprolol compared to those randomized to placebo (table 2). 
After 6 months of follow-up, the scores relevant to physical and emotional dimensions 
as well as the total score decreased (i.e. improved) similarly in both the bisoprolol and 
placebo groups and there was no statistically significant difference between the 
treatment groups (table 2). 
 
FSQ 
At baseline the majority of items in the FSQ questionnaire also indicated moderately 
impaired QoL and there was no statistically significant difference between the two 
treatment groups (table 3). However, the single item ‘general health status’ identified 
a severe reduction in QoL.  
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After 6 months, all but two questionnaire items showed an improvement that was not 
statistically significantly different between treatment groups.  The single item 
question about “days in bed” showed a larger increase in score (i.e. improvement) in 
patients receiving bisoprolol (p = 0.018) compared to those receiving placebo. The 
question about sexual relationships was answered by only about half of patients and 
decreased (i.e. deteriorated) over time (but the change was not different between the 
two treatment groups).  
 
Evaluation of the FSQ and comparison with MLwHF 
Internal consistency (reliability) among related FSQ items was high with Cronbach’s 
Alpha values >0.7 for all items other than “social activity”, where the value was 0.66 
(table 4). Overall construct validity showed good correlations between related 
dimensions as presented in table 5 (e.g. “physical functioning” with “basic” and 
“intermediate activities” showed r = 0.87 and r = 0.95 respectively). Conversely, 
unrelated items were weakly correlated, demonstrating discriminant validity (e.g. 
“mental health” with “basic” and “intermediate activities” showed r = 0.19 and r = 
0.21 respectively). 
Related MLwHF dimensions and FSQ items presented moderate inverse correlations 
(table 6) whereas there was a weak correlation for unrelated sections of the 
questionnaires. 
All the dimensions evaluated by the MLwHF questionnaire indicated significantly 
better QoL for patients in NYHA functional class III compared to patients in NYHA 
IV (table 7A). This was also generally true for the FSQ (table 7B) although the scores 
for the items related to “quality/frequency of interaction” and to “sexual relationship” 
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were not significantly higher (i.e. better). One item, work performance, could not be 
evaluated because only 2 patients in NYHA class IV completed this item.  
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Discussion 
This is the first QoL analysis conducted in patients with moderate to severe CHF 
comparing the generic FSQ questionnaire with the most frequently used disease-
specific MLwHF instrument. The FSQ performed similarly to the latter showing 
comparable accuracy but providing additional information to that obtained with the 
MLwHF. We did not detect any effect of bisoprolol on overall QoL, using either 
questionnaire, after 6 months of follow-up. 
 
In our analysis the QoL scores generated by the MLwHF questionnaire (mean total 
score 40) were consistent with other CHF trials i.e. somewhere between the Valsartan 
Heart Failure Trial (Val-HeFT, mean 32.2) with a larger proportion of NYHA class II 
patients, the Cardiac Resynchronization in Heart Failure study (CARE-HF, mean 45) 
with only class III/IV patients and very similar to the Candesartan in Heart Failure: 
assessment of reduction in mortality and morbidity (CHARM) low LVEF patients 
(median 39), 72% of which were in NYHA class III or IV18,19,20.  
Treatment with bisoprolol did not lead to a significant improvement in overall QoL 
measured using the MLwHF after 6 months of follow-up. This finding is in keeping 
with the Metoprolol CR/XL Randomized International Trial in Congestive Heart 
Failure (MERIT-HF)21 and US Carvedilol programme (USCP)22. 
 
Although the FSQ is a generic tool, the scores obtained using it were generally in 
close agreement with the MLwHF questionnaire highlighting a similar degree of 
impairment of QoL. The majority of scores fell within “warning zones”. Interestingly, 
the single item question in the FSQ about “general health status” gave the score 
indicating the most impaired QoL (mean score=50). While this might be a chance 
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finding, it may, alternatively, indicate that the MLwHF questionnaire and the other 
items in the FSQ fail to capture some important component of QoL in patients with 
CHF.  
 
It is useful to compare the findings with the FSQ in patients in CIBIS-II and the 
findings with the FSQ in other studies. Scores are given for patients in other studies 
and patients in CIBIS-II respectively. Compared with ambulatory geriatric patients, 
our population showed worse QoL in terms of both “basic” (mean score 93.8 vs. 80.9) 
and “intermediate activities of daily living” (77.9 vs. 57.7), “mental health” (77.2 vs. 
67.8), “social activity” (83.8 vs. 69.4) and “quality of interaction” (83.7 vs. 80.5)23. 
The FSQ demonstrated higher QoL in patients with Parkinson’s disease (PD) than in 
our patients24, although scores were lower for “basic” (71.5 vs. 80.9) but higher for 
“intermediate activities of daily living” (64.5 vs. 57.7) in patients with PD. 
Conversely, patients with pulmonary disease had a similar degree of impairment in 
their QoL to patients with CHF (e.g. 83.3 vs. 80.9 for BADL and 52.6 vs. 57.7 for 
IADL)25.  
 
 
The use of the FSQ in addition to the MLwHF questionnaire in a CHF population 
may confer several advantages. The FSQ asks about the number of days that the 
patient has been confined to bed and has reduced his or her daily activities as a result 
of illness. This was the only question from both questionnaires that identified a 
treatment effect of bisoprolol. Although this could be a chance finding, it is certainly 
consistent with the known effect of bisoprolol and other beta-blockers on hospital 
admission rates. 
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The FSQ also has more questions than the MLwHF questionnaire about frequency of 
interaction (how often individuals met with friends/relatives or spoke on the telephone) 
and about the quality of their interaction (how often they had been 
affectionate/irritable/isolated). These facets of the FSQ did not clearly correlate with 
either the physical activity or mental health items on the questionnaire and may  
address a new dimension of patient well-being, as well as provide additional 
information to the single MLwHF question which simply asks the extent to which 
CHF has made socialising difficult.  
The FSQ also asks a question about the patient’s ability to take care of others which 
may be a major factor contributing to QoL if he/she is responsible for 
children/grandchildren or a dependent partner.  
Although the MLwHF does assess sexual relationships the answer is difficult to 
interpret because it is scored between 0-5; a score of 0 could indicate that the patient 
is not sexually active or that he/she is sexually active but dissatisfied with his/her 
sexual activity. The FSQ gives more specific options, including the option of stating 
that the patient did not have sexual relationships in the past month (time frame of the 
questionnaire). Despite this, few patients answered this question; perhaps due to the 
sensitive nature of the topic or because they felt that it was not applicable. This is a 
limitation of this specific item. 
The FSQ assesses the impact of illness on the patient’s mental health without 
explicitly stating the terms “anxiety” or “depression” which can have stigma attached 
to them and may make patients reluctant to answer questions with such labels.  
 
Previously the Short Form-36 (SF-36) and Sickness Impact Profile (SIP) have been 
suggested as the best general QoL instruments for use in CHF. The FSQ offers several 
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potential advantages over both questionnaires in patients with CHF. The FSQ 
separates basic and intermediate activities of daily living, which is relevant as levels 
of physical functioning are impaired to different degrees in CHF: we found that 
intermediate activities of daily living (walking longer distances/climbing stairs/using 
transport/shopping) were more impaired than basic (washing/dressing/moving around 
at home).  In addition the FSQ assesses areas that the SF-36 fails to capture, which are 
especially relevant to heart failure patients: days with restricted activities, days spent 
in bed, satisfaction with sexual relationships and quality of social interactions (in 
addition to frequency of interaction). The FSQ provides information about QoL over 
the past month as opposed to the SIP which assesses QoL only on the day the 
questionnaire is completed. As a result it may be less representative of patients’ 
general QoL and more variable. Also the length of the SIP (136 items) makes it 
burdensome for patients and makes compliance and completeness of follow-up 
suspect. 
 
Several factors could be responsible for the lack of change in QoL during treatment 
with bisoprolol. Neither questionnaire may have addressed determinants of health 
status influenced by beta-blockers or been sensitive enough to detect a change in QoL 
with the sample size studied.  Alternatively, a positive effect of bisoprolol on some 
heart-failure related aspects of QoL might have been diluted by adverse effects on 
other determinants of QoL.  Of course it is also possible that beta-blockers may not 
improve QoL or may take longer than 6 months to do so. However, some measures of 
patient reported overall wellbeing or change in overall wellbeing have identified an 
improvement during relatively short-term beta-blocker treatment. 26, 27, 28 
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This sub-study has several limitations. The sample size was small and the majority of 
patients were NYHA class III. Content validity and the consistency of responses by 
means of test-retest reliability were not assessed. In addition to this, neither 
questionnaire assessed family members’ or care-givers’ QoL and the study was 
conducted in only 3 countries. 
 
Conclusion     
 
This sub-study looking at QoL in CIBIS-II found the FSQ to be an interesting 
instrument with some promising psychometric properties.  The content of the FSQ 
may be especially relevant to CHF patients and further study of it is merited. Despite 
the clear benefits of beta-blockers on survival and hospitalization in CHF, it was not 
possible to demonstrate an improved QoL with bisoprolol although this sub-study 
may have been underpowered. 
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Table 1 Baseline characteristics  
 CIBIS-2 
overall study 
CIBIS-2 Quality of Life Substudy 
  
n=2647 
Total 
n=351 
Bisoprolol 
n=180 
Placebo 
n=171 
p value† 
 
Demographics 
Age (years) 
Height (cm) 
Weight (kg) 
Male sex, n (%) 
White, n (%) 
Black, n (%) 
Oriental, n (%) 
Other, n (%) 
 
60.9 ± 10.5 
170.9 ± 8.1 
78.5 ± 14.0 
2132 (81%) 
2619 (99%) 
8 (<1%) 
16 (1%) 
4 (<1%) 
 
63.2 ± 9.7 
170 ± 8.5 
78.2 ± 14.4 
284 (81%) 
347 (99%) 
1 (<1%) 
2 (<1%) 
1 (<1%) 
 
62.9 ± 10.2 
169 ±  8.4 
77.4 ± 14.9 
146 (81%) 
179 (>99%) 
1 (<1%) 
0 
0 
 
63.6 ±  9.1 
170 ± 8.5 
79.1 ± 13.9 
138 (81%) 
168 (98%) 
0 
2 (1%) 
1 (<1%) 
 
0.769 
0.366 
0.144 
0.922 
 
 
0.174 
Smoking Habit*, n (%) 
Current smoker 
Ex-smoker 
Non-smoker 
 
439 (17%) 
1204 (46%) 
1001 (38%) 
 
46 (13%) 
188 (54%) 
117 (33%) 
 
27 (15%) 
98 (54%) 
55 (31%) 
 
19 (11%) 
90 (53%) 
62 (36%) 
 
 
0.383 
Medical History, n (%) 
Hypertension 
Coronary heart disease 
Myocardial infarction 
PCI 
Cardiac surgery 
Peripheral arterial disease 
Mental health disorder 
 
1150 (44%) 
1719 (65%) 
1455 (55%) 
117 (4%) 
377 (14%) 
196 (7%) 
N/A 
 
133 (38%) 
203 (58%) 
175 (50%) 
34 (10%) 
82 (23%) 
28 (8%) 
38 (11%) 
 
63 (35%) 
111 (62%) 
97 (54%) 
15 (8%) 
46 (26%) 
16 (9%) 
18 (10%) 
 
70 (41%) 
92 (54%) 
78 (46%) 
19 (11%) 
36 (21%) 
12 (7%) 
20 (12%) 
 
0.442 
0.440 
0.369 
0.425 
0.432 
0.550 
0.647 
NYHA class, n (%) 
III 
IV 
 
2202 (83%) 
445 (17%) 
 
323 (92%) 
28 (8%) 
 
162 (90%) 
18 (10%) 
 
161 (94%) 
10 (6%) 
 
0.151 
 
PCI = percutaneous coronary intervention  † Comparison of bisoprolol and placebo groups 
* available in only 2644 patients overall  N/A = not available 
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Table 2 Baseline Minnesota Living With Heart Failure (MLwHF) questionnaire score and 
change between baseline and six months.  A lower score represents better quality of life 
(and a decrease in score an improvement in quality of life). 
 
 Baseline Score 
Difference between baseline and 
6 months 
p value 
 Placebo Bisoprolol Placebo Bisoprolol  
Physical 
dimension 
20.4 (9.9) 
(n = 164) 
21.4 (11.3 ) 
(n = 174) 
-2.8 (8.9) 
(n = 113) 
-3.2 (9.3) 
(n = 122) 
0.709 
Emotional 
dimension 
7.9 (6.0) 
(n = 165) 
8.5 (6.6) 
(n = 174) 
-1.0 (3.8) 
(n = 112) 
-1.3 (4.9) 
(n = 120) 
1.000 
Total score 
39.6 (19.0) 
(n = 165) 
42.0 (20.8) 
(n = 174) 
-4.9 (16.4) 
(n = 112) 
-6.4 (16.1) 
(n = 119) 
0.455 
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Table 3 Functional Status Questionnaire score at baseline and change between baseline and six 
months.  A higher score represents better quality of life (and an increase in score an 
improvement in quality of life). 
 Baseline Score Difference between baseline  
and 6 months 
p value 
 Placebo Bisoprolol Placebo Bisoprolol  
BADL 81.3 (17.6) 
(n = 165) 
80.5 (18.5) 
(n = 172) 
1.5 (18.4) 
(n = 113) 
2.2 (12.2) 
(n = 121) 
0.489 
IADL 58.9 (22.1) 
(n = 164) 
56.4 (24.1) 
(n = 171) 
4.6 (18.3) 
(n = 111) 
7.7 (17.7) 
(n = 118) 
0.226 
Physical functioning 68.9 (18.5) 
(n = 164) 
67.1 (20.0) 
(n = 170) 
3.3 (16.5) 
(n = 111) 
5.2 (13.2) 
(n = 117) 
0.341 
Mental health 68.5 (19.3) 
(n = 164) 
67.1 (19.2) 
(n = 173) 
1.4 (14.3) 
(n = 111) 
4.6 (16.6) 
(n = 118) 
0.229 
Social activity 71.4 (28.9) 
(n = 151) 
67.3 (30.2) 
(n = 161) 
6.9 (20.3) 
(n = 97) 
10.4 (26.0) 
(n = 106) 
0.430 
Quality of interaction 80.2 (15.9) 
(n = 164) 
80.7 (13.6) 
(n = 172) 
2.2 (14.1) 
(n = 112) 
-0.2 (12.4) 
(n = 117) 
0.157 
Work performance 72.9 (24.9) 
(n = 23) 
67.8 (25.8) 
(n = 19) 
0.0 (18.2) 
(n = 12) 
15.3 (24.3) 
(n = 12) 
0.116 
Social role functioning 77.3 (15.9) 
(n = 128) 
76.7 (14.6) 
(n = 140) 
3.1 (11.7) 
(n = 79) 
1.9 (11.2) 
(n = 90) 
0.522 
Frequency of interaction 63.1 (26.9) 
(n = 161) 
65.8 (26.0) 
(n = 169) 
0.0 (29.6) 
(n = 107) 
-0.7(28.4) 
(n = 115) 
0.814 
Sexual relationships 47.8 (31.4) 
(n = 68) 
52.7 (30.2) 
(n = 83) 
-2.0 (24.6) 
(n = 37) 
-1.4 (22.5) 
(n = 54) 
0.883 
Days in bed 91.9 (18.4) 
(n = 161) 
89.1 (20.4) 
(n = 173) 
-0.7 (20.5) 
(n = 109) 
3.9 (16.8) 
(n = 118) 
0.018 
Days with restricted 
activities 
70.9 (35.2) 
(n = 158) 
67.5 (38.5) 
(n = 167) 
8.8 (40.2) 
(n = 106) 
13.6 (36.9) 
(n = 113) 
0.438 
General health status 42.7 (26.3) 
(n = 161) 
42.4 (26.2) 
(n = 172) 
15.9 (27.0) 
(n = 110) 
16.0 (29.7) 
(n = 120) 
0.935 
 
BADL = Basic activities of daily living (see text).   IADL = Intermediate activities of daily living (see text) 
     27 
Table 4A Internal reliability of the Functional Status Questionnaire. 
 
Dimensions and sub-dimensions N= Cronbach α 
Basic activities of daily living 337 0.776 
Intermediate activities of daily living 335 0.793 
Physical functioning 334 0.861 
Mental health 337 0.779 
Social activity 312 0.806 
Social interaction 336 0.656 
Work performance 42 0.799 
Social role function (active) 40 0.783 
Social role function (non active) 268 0.709 
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Table 4B Internal reliability of the Minnesota Living with Heart Failure Questionnaire 
 
Dimensions and sub-dimensions N= Cronbach α 
Physical Dimension 314 0.898 
Emotional Dimension 333 0.825 
Total Score 296 0.892 
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Table 5 Pearson’s correlations matrix at baseline for Functional Status Questionnaire (FSQ). 
Scales Basic 
activities 
Intermed. 
activities 
Physical 
function. 
Mental 
Health 
Social 
activity 
Social 
interact. 
Work 
perform. 
Social/role 
function 
Basic activities 1.00 
(n = 337) 
       
Intermed. 
Activities 
0.68 
(n = 334) 
1.00 
(n = 335) 
      
Physical 
function. 
0.87 
(n = 334) 
0.95 
(n = 334) 
1.00 
(n = 334) 
     
Mental Health 0.19 
(n = 334) 
0.21 
(n = 332) 
0.22 
(n = 331) 
1.00 
(n =337) 
    
Social activity 0.59 
(n = 312) 
0.76 
(n = 309) 
0.75 
(n = 309) 
0.29 
(n = 309) 
1.00 
(n = 312) 
   
Quality of 
interaction 
0.20 
(n = 333) 
0.23 
(n = 331) 
0.23 
(n = 330) 
0.54 
(n = 336) 
0.25 
(n = 308) 
1.00 
(n = 336) 
  
Work perform. 0.13 
(n = 42) 
0.19 
(n = 42) 
0.19 
(n = 42) 
0.08 
(n = 42) 
0.09 
(n = 40) 
0.40 
(n = 42) 
1.00 
(n = 42) 
 
Social/role 
function 
0.45 
(n = 308) 
0.55 
(n = 305) 
0.56 
(n = 305) 
0.54 
(n = 308) 
0.68 
(n = 308) 
0.85 
(n = 308) 
0.85 
(n = 40) 
1.00 
(n = 308) 
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Table 6 Pearson’s correlations matrix at baseline for Functional Status Questionnaire (FSQ) and 
Minnesota Living With Heart Failure (MLWHF) questionnaire. 
 
 MLWHF 
FSQ Physical dimension Emotional dimension 
BADL -0.58  
(n =334) 
-0.36  
(n = 335) 
IADL -0.66  
(n =332) 
-0.38  
(n = 333) 
Physical functioning -0.68  
(n = 331) 
-0.41  
(n = 332) 
Mental Health -0.28  
(n = 334) 
-0.61  
(n = 335) 
Social Activity -0.58  
(n = 311) 
-0.41  
(n = 311) 
Quality of interaction -0.24 
(n = 333) 
-0.47  
(n = 334) 
Work performance -0.27  
(n = 41) 
-0.33  
(n = 42) 
Social role function -0.48  
(n = 307) 
-0.57  
(n = 307) 
 
BADL = Basic activities of daily living (see text).   IADL = Intermediate activities of daily living (see text) 
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Table 7A Minnesota Living With Heart Failure (MLwHF) questionnaire scores by New York 
Heart Association (NYHA) functional classification at baseline. 
 
 NYHA III NYHA IV p value 
Physical dimension of MLwHF 20.1 (10.3) 
(n = 310) 
 
29.6 (10.1) 
(n = 28) 
< 0.0001 
Emotional dimension of MLwHF 8.0 (6.1) 
(n = 311) 
11.1 (7.7) 
(n = 28) 
 
0.0473 
Total score of MLwHF 39.6 (19.6) 
(n = 311) 
 
54.6 (19.2) 
(n = 28) 
 
0.0004 
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Table 7B Functional Status Questionnaire (FSQ) scores by New York Heart Association (NYHA) 
functional classification at baseline. 
 NYHA III NYHA IV p value 
BADL 82.5 (16.5) 
(n = 309) 
63.8 (24.7) 
(n = 28) 
0.0004 
IADL 59.4 (22.4) 
(n = 307) 
38.6 (22.7) 
(n = 28) 
0.0001 
Physical functioning 69.7 (18.1) 
(n = 306) 
49.8 (21.7) 
(n = 28) 
0.0001 
Mental health 68.7 (18.6) 
(n = 310) 
57.0 (23.1) 
( n = 27) 
0.0159 
Social activity 71.3 (28.8) 
(n = 284) 
48.4 (30.1) 
(n = 28) 
0.0005 
Quality of interaction 80.7 (15.0) 
(n = 309) 
77.3 (11.9) 
(n = 27) 
0.1711 
Work performance 69.5 (25.3) 
(n = 40) 
91.7 (3.9) 
(n = 2) 
N/A 
Social role functioning 77.9 (15.1) 
(n = 243) 
68.9 (14.1) 
(n = 25) 
0.0051 
Frequency of interaction 65.5 (25.8) 
(n = 303) 
53.3 (30.9) 
(n = 27) 
0.0531 
Sexual relationships 50.7 (30.8) 
(n = 143) 
46.9 (31.2) 
(n = 8) 
0.7425 
Days in bed 91.9 (17.3) 
(n = 307) 
74.1 (32.3) 
(n = 27) 
0.0079 
Days with restricted activities 71.2 (36.1) 
(n = 300) 
44.0 (38.2) 
(n = 25) 
0.0007 
General health status 44.1 (26.0) 
(n = 307) 
25.0 (22.4) 
(n = 26) 
0.0003 
 
BADL = Basic activities of daily living (see text).   IADL = Intermediate activities of daily living (see text) 
N/A = statistical comparison not appropriate 
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Figure 1: Histogram showing baseline Functional Status Questionnaire (FSQ) scores and “warning zones” 
– the score below which there is a clinically important reduction in quality of life for that domain. 
 
 
0
10
20
30
40
50
60
70
80
90
100
BA
DL IAD
L
Me
nta
l H
eal
th
So
cia
l a
ctiv
ity
Qu
ali
ty o
f in
ter
act
ion
Wo
rk 
per
for
ma
nc
e
Warning zone upper limit
Actual FSQ Scores
 
 
 
 
 
 
 
 
 
 
